Viewing Study NCT06040320


Ignite Creation Date: 2025-12-25 @ 4:16 AM
Ignite Modification Date: 2025-12-26 @ 3:16 AM
Study NCT ID: NCT06040320
Status: RECRUITING
Last Update Posted: 2025-10-28
First Post: 2023-09-09
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Sponsor: Washington University School of Medicine
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module